Nuformix Plc (LON:NFX), a pharmaceutical development company focused on drug repurposing for fibrosis and oncology, recently provided a patent update for its NXP002 and NXP004 programs, as well as its interim results.
In this interview with Nuformix Executive Director Dr. Dan Gooding, the discussion covers the significance of these patents in advancing their programs, particularly NXP002, which is aimed at treating lung fibrosis with an inhaled therapy. The update also highlights the company’s lean management approach and ongoing efforts to secure development partners. Dan outlines the next steps for Nuformix, emphasising their commitment to progressing their drug programs and finding suitable partners for further development.
